NanoMosaic received Advanced Manufacturing Technology (AMT) designation from the U.S. FDA for its Tessie platform, which quantifies vector genome integrity and capsid titers during AAV manufacturing. The designation offers enhanced FDA engagement and potential prioritization for IND and BLA review for gene‑therapy developers that deploy Tessie as a critical quality assessment tool. NanoMosaic CEO Philippe Mourere said the AMT status validates the company’s nanoneedle multiplex testing approach and its ability to deliver actionable critical quality attributes for AAV potency and batch consistency. Tessie measures full‑length transgene integrity directly from crude or purified samples and multiplexes protein and nucleic‑acid biomarkers. The decision signals FDA interest in analytical technologies that reduce regulatory uncertainty for cell and gene therapies and could accelerate adoption of inline QC platforms across CDMOs and sponsors.